Ticagrelor is Associated with Increased Rosuvastatin Blood Concentrations in Patients who have had a Myocardial Infarction
Clinical Pharmacokinetics · 2025
DOI: 10.1007/s40262-025-01489-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacokinetics, 2025. Verfasst von Tjaša Dermota und 3 weiteren Autor:innen. Beteiligte Einrichtung: University Medical Centre Ljubljana, Zaloška cesta 7, 1000, Ljubljana, Slovenia. tjasa.dermota@kclj.si. Hauptthemen laut MEDLINE: Rosuvastatin Calcium, Myocardial Infarction, Purinergic P2Y Receptor Antagonists, Adenosine. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Javna Agencija za Raziskovalno Dejavnost RS.
Abstract (Originalsprache)
AIMS: The primary objective of this study was to determine whether concomitant therapy with ticagrelor and rosuvastatin affects rosuvastatin plasma concentrations in patients receiving rosuvastatin 40 mg/day after myocardial infarction. METHODS: We included 93 patients who had experienced a myocardial infarction and were receiving high-dose rosuvastatin 40 mg/day and a P2Y12 receptor antagonist, either ticagrelor, prasugrel or clopidogrel. We used liquid chromatography with tandem mass spectrometry to measure rosuvastatin plasma concentrations after liquid-liquid extraction. RESULTS: Rosuvastatin plasma concentrations (9.7 ng/mL) were approximately twice as high in patients receiving ticagrelor therapy as in those receiving prasugrel (5.1 ng/mL, p < 0.001) or clopidogrel (5.0 ng/mL, p = 0.009), and ticagrelor was an independent factor influencing rosuvastatin concentrations. In addition, creatinine levels were associated with increased rosuvastatin concentrations (p = 0.039). CONCLUSION: Our results suggest an important pharmacokinetic interaction between ticagrelor and rosuvastatin, leading to approximately two-fold higher rosuvastatin plasma concentrations in those receiving concomitant ticagrelor than in those receiving prasugrel or clopidogrel. The association is significant and independent of other potential factors influencing rosuvastatin levels, indicating its potential clinical relevance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University Medical Centre Ljubljana, Zaloška cesta 7, 1000, Ljubljana, Slovenia. tjasa.dermota@kclj.si.
- Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia. tjasa.dermota@kclj.si.
- University Medical Centre Ljubljana, Zaloška cesta 7, 1000, Ljubljana, Slovenia.
- Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
ORCID-Profile: Tjaša Dermota, Borut Jug, Mojca Božič Mijovski
Förderung
- Javna Agencija za Raziskovalno Dejavnost RS
Zitieren
APA
Dermota, T., Jug, B., Trontelj, J., & Božič Mijovski, M. (2025). Ticagrelor is Associated with Increased Rosuvastatin Blood Concentrations in Patients who have had a Myocardial Infarction. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-025-01489-1
Vancouver
Dermota T, Jug B, Trontelj J, Božič Mijovski M. Ticagrelor is Associated with Increased Rosuvastatin Blood Concentrations in Patients who have had a Myocardial Infarction. Clinical Pharmacokinetics. 2025. doi:10.1007/s40262-025-01489-1
BibTeX
@article{Dermota2025,
author = {Dermota, Tjaša and Jug, Borut and Trontelj, Jurij and Božič Mijovski, Mojca},
title = {Ticagrelor is Associated with Increased Rosuvastatin Blood Concentrations in Patients who have had a Myocardial Infarction},
journal = {Clinical Pharmacokinetics},
year = {2025},
doi = {10.1007/s40262-025-01489-1}
}
EUVIMED